Randomized Trials
[Preprint] RCT: Both REGEN-COV 2400mg and 1200mg antibody cocktails significantly reduced Covid-19-related hospitalization or all-cause death compared to placebo (71.3% reduction and 70.4% reduction, respectively).
24 May, 2021 | 08:46h | UTCREGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients – medRxiv
Commentary on Twitter
REGEN-COV Antibody Cocktail(casirivimab with imdevimab) Clinical Outcomes Study in Covid-19 Outpatients: N:>4000 pts
Both 1200mg IV&2400mg REGEN-COV led to a ≥70% ⬇️ (vs placebo) in Covid-19 hospitalization or all-cause death over 28 days after treatmenthttps://t.co/NJxF4BjZRs pic.twitter.com/CFdvEEIWEL— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) May 21, 2021
#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.
24 May, 2021 | 08:28h | UTCUltrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: Renal Denervation for Resistant Hypertension Is Not Back on Track – “A systolic blood pressure (SBP) reduction of 4.5 mm Hg is not good enough—for an invasive procedure”. – Medscape (free registration required)
RCT: Among patients with pemphigus vulgaris, rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks (40% vs 10%) but was associated with increased risk of serious adverse events (22% vs. 15%).
24 May, 2021 | 08:24h | UTC
RCT: In Africa, children hospitalized with severe pneumonia with oxygen saturations between 80 and 91% who did not receive oxygen had comparable mortality to children who received oxygen.
21 May, 2021 | 08:30h | UTC
Commentary on Twitter
COAST RCT O2 in African children >28 days w severe pneumonia, less is more!
SO2 80-91%? no O2 ➡️48h mortality comparable to low-flow O2/HFNC. O2-sparing strategies potentially offer cost-effective approaches to reduce requirements in low resource settings. https://t.co/8JHit94WQY pic.twitter.com/EEIybSOlmy— Intensive Care Medicine (@yourICM) May 6, 2021
SPRINT Trial final report: targeting a systolic BP of less than 120 mm Hg in patients at increased CV risk is associated with improved CV and mortality outcomes but increases the risk of serious adverse events.
20 May, 2021 | 08:36h | UTC
24-week randomized controlled trial: Mixed tree nut snacks resulted in similar weight loss and increased satiety compared to refined carbohydrate snacks in a weight loss and maintenance program.
20 May, 2021 | 08:28h | UTCCommentary: Mixed tree nut snacks result in significant weight loss and improved satiety – News Medical
[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.
18 May, 2021 | 08:04h | UTCTherapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv
Commentary on Twitter
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. https://t.co/TkhGs5qow5
— Ryan Zarychanski (@RZarychanski) May 17, 2021
RCT: Among patients with esophageal cancer, intrathoracic anastomosis after totally or hybrid minimally invasive esophagectomy resulted in lower anastomotic leakage rates and better outcomes when compared with cervical anastomosis.
18 May, 2021 | 07:21h | UTCIntrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited commentary: Does the Location Matter for the Anastomosis for Minimally Invasive Esophagectomy? (free for a limited period)
Commentary on Twitter
Intrathoracic anastomosis after MIE is associated with a lower anastomotic leakage rate and better outcome for patients with mid to distal esophageal or gastro-esophageal junction cancer: results of the ICAN trial https://t.co/CXv2CeCnuX pic.twitter.com/QCYg4UJeyF
— JAMA Surgery (@JAMASurgery) May 12, 2021
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
17 May, 2021 | 08:49h | UTC
Commentaries on Twitter
DARE-19 trial #ACC21 @ACCinTouch
Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile
🎯 Do not discontinue SGLT2i in 🏥 for #COVID19
Full slideset available in 👇https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu
— Enrique Santas (@SantasEnrique) May 16, 2021
DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ
— American College of Cardiology (@ACCinTouch) May 16, 2021
#ACC21 – Practice Changing RCT: In patients with atrial fibrillation (75% maintained on anticoagulation), left atrial appendage occlusion during cardiac surgery reduces the incidence of stroke and systemic embolism (4.8 vs. 7.0%) in the following years.
17 May, 2021 | 08:33h | UTCLeft Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Simple surgery prevents strokes in heart patients – McMaster University AND Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III – TCTMD
Video: The Left Atrial Appendage Occlusion Study (LAAOS) III
Commentary on Twitter
A visual abstract of the #ACC21 Left Atrial Appendage Occlusion Study III is now available, evaluating surgical #LAAO compared with no occlusion among patients with #AFib undergoing open heart surgery for another indication. https://t.co/3iIhAEuGwk pic.twitter.com/e9Wq6Bp3Zz
— American College of Cardiology (@ACCinTouch) May 15, 2021
#ACC21 – RCT: No significant differences in cardiovascular events or major bleeding between patients receiving 81 mg vs. 325 mg of aspirin daily.
17 May, 2021 | 08:31h | UTCComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE – TCTMD AND Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness – ADAPTABLE – American College of Cardiology
Video: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
#ACC21 – RCT: Tailored, earlier heart failure rehabilitation program has physical and emotional benefits for older patients.
17 May, 2021 | 08:23h | UTCCommentaries: Tailored, earlier heart failure rehab has physical, emotional benefits for patients – National institutes of Health AND REHAB-HF: Tailored Cardiac Rehab Program Improved Function and Quality of Life in Older HF Patients – American College of Cardiology AND Rehabilitation Therapy in Older Acute Heart Failure Patients – REHAB-HF – American College of Cardiology
Commentaries on Twitter
#REHAB-HF #ACC21 innovative intensive rehab improved physical function
-attention to SDOH environment assessment & involvement of family/care givers
-q2 wk trouble shooting discussion
-corrected balance/mobility first to get pts on treadmill w confidence https://t.co/rOmsc6qdq3 pic.twitter.com/V8TugBipUT— Ritu Thamman MD (@iamritu) May 16, 2021
REHAB-HF trial results found novel #CVRehab program tailored to address specific physical impairments in frail/older patients w/ acute #HeartFailure improved physical function & quality of life; did not significantly reduce hospitalizations. https://t.co/f98IdMvqj4 #ACC21 #cvGeri pic.twitter.com/zY8E1WBNmf
— American College of Cardiology (@ACCinTouch) May 16, 2021
#ACC21 – RCT: In patients with STEMI undergoing complete revascularization, an FFR-guided strategy did not improve outcomes compared to an angiography-guided strategy.
17 May, 2021 | 08:26h | UTCMultivessel PCI Guided by FFR or Angiography for Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)
#ACC21 – [Not published yet] RCT: PARADISE-MI: Sacubitril/Valsartan did not outperform ACE inhibitor after myocardial infarction with new onset heart failure.
17 May, 2021 | 08:17h | UTC
#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).
17 May, 2021 | 08:19h | UTCCommentaries: ATLANTIS: Apixaban Not Superior to Standard Care After TAVR – American College of Cardiology AND ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI – TCTMD
Pragmatic RCT: Among patients with advanced glaucoma, primary trabeculectomy resulted in similar quality of life and safety outcomes and achieved a lower intraocular pressure compared with primary medication.
17 May, 2021 | 08:06h | UTC
Large trial with over 200.000 patients finds ovarian cancer screening does not reduce deaths.
14 May, 2021 | 08:32h | UTCCommentaries: Screening for ovarian cancer did not reduce early deaths – Imperial College London AND Annual screening for ovarian cancer does not save lives, study finds – The Guardian
RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.
14 May, 2021 | 08:25h | UTCCommentary: New drug shows promise against tough-to-manage asthma – MedicalXpress
RCT: Tympanostomy-tube placement does not reduce episodes of acute otitis media among children 6 to 35 months of age with recurrent acute otitis media
13 May, 2021 | 05:57h | UTCCommentary: No lasting benefit to tubes over antibiotics for childhood ear infections – University of Pittsburgh
RCT: Among adults with idiopathic pulmonary fibrosis, antimicrobial therapy with co-trimoxazole or doxycycline is not associated with improved outcomes.
12 May, 2021 | 08:37h | UTCEffect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among adults with idiopathic pulmonary fibrosis, addition of co-trimoxazole or doxycycline compared with usual care did not significantly improve the time to nonrespiratory hospitalization or death https://t.co/t6WQ2sifx0
— JAMA (@JAMA_current) May 11, 2021
RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.
10 May, 2021 | 00:46h | UTC18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)
RCT: Efficacy and safety of voclosporin for lupus nephritis – voclosporin + MMF + low dose corticosteroids achieved complete renal response at week 52 more often than MMF + low dose corticosteroids alone (41% vs. 23%).
10 May, 2021 | 00:48h | UTCEfficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT: Community pharmacies provision of a progestogen-only pill + invitation to a sexual and reproductive health clinic as a bridging contraception intervention for women receiving emergency contraception is associated with increased subsequent use of long-term effective contraception.
10 May, 2021 | 00:45h | UTC
RCT: Therapeutic drug monitoring during infliximab induction does not improve disease remission in patients with chronic immune-mediated inflammatory diseases
7 May, 2021 | 08:27h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)
Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Commentary on Twitter
Study findings do not support routine use of proactive therapeutic drug monitoring during infliximab induction for improving immune-mediated inflammatory disease remission rates https://t.co/sDslkVm3u9
— JAMA (@JAMA_current) May 5, 2021